232 related articles for article (PubMed ID: 15447744)
1. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.
El-Serag HB; Aguirre TV; Davis S; Kuebeler M; Bhattacharyya A; Sampliner RE
Am J Gastroenterol; 2004 Oct; 99(10):1877-83. PubMed ID: 15447744
[TBL] [Abstract][Full Text] [Related]
2. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
3. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
4. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
Gurski RR; Peters JH; Hagen JA; DeMeester SR; Bremner CG; Chandrasoma PT; DeMeester TR
J Am Coll Surg; 2003 May; 196(5):706-12; discussion 712-3. PubMed ID: 12742201
[TBL] [Abstract][Full Text] [Related]
5. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
6. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
7. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
8. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of Barrett's esophagus length.
Dickman R; Green C; Chey WD; Jones MP; Eisen GM; Ramirez F; Briseno M; Garewal HS; Fass R
Gastrointest Endosc; 2005 Nov; 62(5):675-81. PubMed ID: 16246678
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
11. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
[TBL] [Abstract][Full Text] [Related]
12. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
13. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma.
Guardino JM; Khandwala F; Lopez R; Wachsberger DM; Richter JE; Falk GW
Am J Gastroenterol; 2006 Oct; 101(10):2187-93. PubMed ID: 17032182
[TBL] [Abstract][Full Text] [Related]
14. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
15. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Siersema PD; Yu S; Sahbaie P; Steyerberg EW; Simpson PW; Kuipers EJ; Triadafilopoulos G
Gastrointest Endosc; 2006 Apr; 63(4):581-6. PubMed ID: 16564855
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ;
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977
[TBL] [Abstract][Full Text] [Related]
17. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
El-Serag HB; Wieman M; Richardson P
Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
19. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
[TBL] [Abstract][Full Text] [Related]
20. The economic impact of the diagnosis of dysplasia in Barrett's esophagus.
Ofman JJ; Lewin K; Ramers C; Ippoliti A; Lieberman D; Weinstein W
Am J Gastroenterol; 2000 Oct; 95(10):2946-52. PubMed ID: 11051373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
